Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Razoxane for Crohn's colitis and non-specific proctitis.

R D Kingston1, K Hellman

  • 1Department of Clinical Studies, Trafford General Hospital, Davyhulme, Manchester.

The British Journal of Clinical Practice
|January 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cancer in young adulthood - classifying the intensity of treatment.

Acta oncologica (Stockholm, Sweden)·2022
Same author

Human papillomavirus, p16(INK4A), and Ki-67 in relation to clinicopathological variables and survival in primary carcinoma of the vagina.

British journal of cancer·2014
Same author

Impact of genomic stability on protein expression in endometrioid endometrial cancer.

British journal of cancer·2012
Same author

Differential expression of ANXA6, HSP27, PRDX2, NCF2, and TPM4 during uterine cervix carcinogenesis: diagnostic and prognostic value.

British journal of cancer·2010
Same author

Differential tissue-specific protein markers of vaginal carcinoma.

British journal of cancer·2009
Same author

A relationship between perioperative blood transfusion and recurrence of carcinoma of the sigmoid colon following potentially curative surgery.

Annals of the Royal College of Surgeons of England·2009

Oral razoxane effectively induced remission in active Crohn's disease and proctitis patients. This treatment led to sustained remission without relapses or surgery, demonstrating a favorable safety profile with minimal toxicity.

Area of Science:

  • Gastroenterology
  • Pharmacology
  • Clinical Medicine

Background:

  • Crohn's disease is a chronic inflammatory bowel disease requiring effective treatment.
  • Active proctitis also necessitates prompt and safe therapeutic interventions.

Purpose of the Study:

  • To evaluate the efficacy and safety of oral razoxane in patients with active Crohn's disease.
  • To assess the impact of oral razoxane on active non-specific proctitis.

Main Methods:

  • Nine patients with active Crohn's disease received oral razoxane 125 mg daily.
  • Two patients with active non-specific proctitis were also treated with oral razoxane 125 mg daily.
  • Treatment was primarily conducted on an outpatient basis.

Main Results:

Related Experiment Videos

  • Oral razoxane achieved remission in all nine patients with active Crohn's disease, though remissions took several months.
  • No relapses or surgical interventions were required in Crohn's disease patients during treatment.
  • Oral razoxane rapidly controlled active non-specific proctitis in two patients.
  • Mild bone marrow toxicity was observed in one patient; no other acute or long-term side-effects were noted.

Conclusions:

  • Oral razoxane is a potentially effective treatment for active Crohn's disease and active non-specific proctitis.
  • The drug demonstrates a favorable safety profile with minimal toxicity in the studied patients.
  • Sustained remission and avoidance of surgery highlight the therapeutic potential of oral razoxane.